Axon Enterprise (NASDAQ:AXON – Get Free Report) had its price objective lifted by investment analysts at Barclays from $308.00 to $381.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 23.27% from the stock’s previous close.
Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Tuesday. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. TheStreet downgraded shares of Axon Enterprise from a “b” rating to a “c+” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. raised their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Finally, StockNews.com downgraded Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $333.08.
Get Our Latest Stock Report on AXON
Axon Enterprise Stock Down 0.9 %
Shares of Axon Enterprise stock opened at $309.09 on Wednesday. Axon Enterprise has a 52-week low of $175.37 and a 52-week high of $329.87. The firm’s 50 day moving average price is $310.86 and its 200-day moving average price is $267.73. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42. The company has a market cap of $23.32 billion, a P/E ratio of 90.38 and a beta of 0.91.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. The business had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. The business’s quarterly revenue was up 34.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.51 earnings per share. On average, sell-side analysts predict that Axon Enterprise will post 2.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Axon Enterprise
Several hedge funds have recently added to or reduced their stakes in AXON. Vanguard Group Inc. raised its stake in shares of Axon Enterprise by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 7,930,905 shares of the biotechnology company’s stock valued at $2,048,791,000 after buying an additional 40,435 shares during the last quarter. Sands Capital Management LLC grew its holdings in Axon Enterprise by 0.6% during the fourth quarter. Sands Capital Management LLC now owns 2,628,652 shares of the biotechnology company’s stock worth $679,060,000 after acquiring an additional 16,347 shares during the period. Wellington Management Group LLP raised its position in Axon Enterprise by 3.3% during the third quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company’s stock valued at $389,229,000 after acquiring an additional 62,324 shares in the last quarter. Norges Bank purchased a new position in Axon Enterprise during the fourth quarter valued at approximately $195,406,000. Finally, Westfield Capital Management Co. LP lifted its holdings in Axon Enterprise by 5.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 731,721 shares of the biotechnology company’s stock valued at $189,025,000 after acquiring an additional 35,528 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
